Previous 10 | Next 10 |
The pandemic spurred many significant and sticky consequences for life in the future. It changed how we live in many ways that will never return to pre-pandemic cultural habits. Late adopters of ecommerce are a good example. Zoom meetings versus flying across the country are another. One of t...
The stock market is nothing but volatile, and the market has made itself clear with that at the start of 2021. The SPDR S&P 500 ETF (NYSEMKT: SPY) is down over 7% year to date, with 2022 lows being 9% down and highs being in the positive territory for the year. For long-term...
Doximity's New Report Finds Adoption of Telemedicine Growing, Majority of Patients Plan for Virtual Care Post-Pandemic Over 73% of patients plan to have telemedicine visits after the pandemic; nearly 60% of patients prefer mobile devices for telemedicine; telemedicine adoption a...
Shares of Doximity (NYSE: DOCS) popped recently in response to a quarterly earnings report chock-full of good news. A disturbingly high market valuation, though, is leading some investors to wonder if it's already too late to buy the stock at a fair price. Outstanding performa...
Doximity (NYSE: DOCS) is one of the leading digital platforms for U.S. medical professionals and students. The company aims to help physicians be more productive in the workplace and provide better care by offering collaboration tools, telehealth services, and newsfeeds for its user...
Goldman Sachs has initiated Teladoc (TDOC +5.7%) and Doximity (DOCS -3.9%) with buy ratings as the firm has a positive view on the healthcare technology sector for the long term. Analyst Cindy Motz writes that the digital healthcare solutions the two companies provide will greatly assist heal...
Owning growth stocks is a great way to potentially boost your portfolio's gains, but knowing how to select the right companies that are poised to be long-term winners isn't always easy. And even when you find a few great companies, you'll have to stomach some potential volatility as...
Shares of Doximity (NYSE: DOCS) leaped 24% on Wednesday after the networking platform for medical professionals announced strong third-quarter growth metrics. Doximity's revenue surged 67% year over year to $97.9 million in its fiscal 2022 third quarter, which ended on Dec. ...
Doximity (DOCS +22.8%) shares are soaring today after its fiscal Q3 2022 results yesterday after the bell beat on the top and bottom lines and it issues strong 2022 guidance. Revenue for the quarter surged ~67% year over year, while GAAP net income more than tripled from the previous year...
Gainers: Doximity (NYSE:DOCS) +20%. Aptevo Therapeutics (NASDAQ:APVO) +17%. Biofrontera (NASDAQ:BFRA) +14%. Karyopharm Therapeutics (NASDAQ:KPTI) +14%. Teva Pharmaceutical (NYSE:TEVA) +9%. Losers: Varex Imaging (NASDAQ:VREX) -11%. BioCardia (NASDAQ...
News, Short Squeeze, Breakout and More Instantly...
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Doximity, Inc. (NYSE: DOCS). On August 8, 2023, the Company disclosed disappointing guidance ...
Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, today announced it will report financial results for its fiscal first quarter ended June 30, 2024 after market close on August 8, 2024. Doximity will host a conference call and webcast at 2:00 p.m. PT (5:00 p...
2024-07-10 22:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...